Michele Leuenberger

Michele Leuenberger

Auto-generated profile, based on publicly available information

Michele Leuenberger

Department of Chemistry and Biochemistry, University of Bern , 3012 Bern, Switzerland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
YKYoshikatsu Kanai
Yoshikatsu Kanai
BCBenjamin Clémençon
Benjamin Clémençon
ASAlexandre Simonin
Alexandre Simonin
MLMichele Leuenberger
Michele Leuenberger
Martin LochnerMartin Lochner
Martin Lochner
MHMatthias A. Hediger
Matthias A. Hediger

16 July 2001 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MLMichele G. Leuenberger
Michele G. Leuenberger
CECaroline Engeloch-Jarret
Caroline Engeloch-Jarret
WWWolf-D. Woggon
Wolf-D. Woggon

1 February 1998 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
TWThomas Wirth
Thomas Wirth
SHSara Häuptli
Sara Häuptli
MLMichele Leuenberger
Michele Leuenberger

3 April 2000 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
RFRichard R. French
Richard R. French
PHPhilipp Holzer
Philipp Holzer
MLMichele G. Leuenberger
Michele G. Leuenberger
WWWolf-D. Woggon
Wolf-D. Woggon

1 June 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AHAlexandre Hofer
Alexandre Hofer
GKGergely Kovacs
Gergely Kovacs
AZAnna Zappatini
Anna Zappatini
MLMichele Leuenberger
Michele Leuenberger
MHMatthias A. Hediger
Matthias A. Hediger
Martin LochnerMartin Lochner
Martin Lochner

18 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
Mark J WallMark J Wall
Mark J Wall
EHEmily Hill
Emily Hill
RHRobert Huckstepp
Robert Huckstepp
KBKerry Barkan
Kerry Barkan
GDGiuseppe Deganutti
Giuseppe Deganutti
BFBruno G. Frenguelli
Bruno G. Frenguelli
The development of therapeutic agonists for G protein-coupled receptors (GPCRs) is hampered by the propensity of GPCRs to couple to multiple intracellular signalling pathways. This promiscuous coupling leads to numerous downstream cellular effects, some of which are therapeutically undesirable. This is especially the case for adenosine A1 receptors (A1Rs) whose clinical potential is undermined by the sedation and cardiorespiratory depression caused by conventional agonists. We have discovered that the A1R-selective agonist, benzyloxy-cyclopentyladenosine (BnOCPA), is a potent and powerful analgesic but does not cause sedation, bradycardia, hypotension or respiratory depression. This unprecedented discrimination between native A1Rs arises from BnOCPA’s unique and exquisitely selective activation of Gob among the six Gαi/o subtypes, and in the absence of β-arrestin recruitment. BnOCPA thus demonstrates a highly-specific Gα-selective activation of the native A1R, sheds new light on GPCR signalling, and reveals new possibilities for the development of novel therapeutics based on the far-reaching concept of selective Gα agonism.